Giovanni Caforio appointed Bristol-Myers Squibb COO
NEW YORK—Bristol-Myers Squibb has appointed Giovanni Caforio, M.D., as COO.
The pharmaceutical company announced Monday that Carforio, who has been with Bristol-Myers Squibb since 2000, had been appointed COO and elected to its board of directors. Since 2011, Caforio has been the company’s chief commercial officer, a job whose duties he’ll continue doing alongside his new position’s focus on spearheading enterprise services and global manufacturing and supply.
Before taking on his position as COO, Caforio headed Brisol-Myers Squibb’s departments of U.S. and global oncology, and had overseen European markets before that.
"Giovanni brings valuable experience to the role, from his training as a physician to his strong record in key leadership positions in marketing and operations in Europe, the United States and commercial," the company’s CEO, Lamberto Andreotti said, adding that his appointment and election to the board of directors is "an honor that recognizes his commitment and contributions to our company."
Purely Elizabeth makes Target debut
NEW YORK — Purely Elizabeth, a natural foods company, announced that its line of Ancient Grain Granola debuted at Target stores across the country on June 8. Consumers can choose from original, pumpkin fig and cranberry pecan varieties.
“Target has made huge strides toward making natural, organic and sustainable products more accessible to consumers nationwide, and we couldn’t be more thrilled to be a part of that movement,” said Elizabeth Stein, founder and CEO of Purely Elizabeth. “To be able to have a healthier breakfast alternative now available to such a wide customer base is quite an honor and speaks volumes to the shift in consumer demand for better-for-you products.”
Purely Elizabeth is made with organic coconut sugar and organic virgin coconut oil. In addition to being handcrafted and baked in small batches, the product is made of organic gluten-free oats and ancient grains and seeds, including Salba chia seeds, puffed amaranth, hemp seeds and quinoa flakes, the company said.
FDA approves BDSI’s NDA for Bunavail
RALEIGH, N.C. — BioDelivery Sciences International on Monday announced that the Food and Drug Administration approved its new drug application for Bunavail (buprenorphine and naloxone) buccal film (CIII). The drug is used as a maintenance treatment of opioid dependence. The company noted that it also should be used as part of a complete treatment plan to include counseling and psychosocial support.
Bunavail is the first and only formulation of buprenorphine and naloxone for buccal (inside of the cheek) administration, BDSI said.
"Bunavail is a novel treatment approach for the more than two million people in the United States afflicted with opioid dependence," said Gregory Sullivan, M.D., principal investigator of the Phase 3 Bunavail safety study and an addiction specialist and Medical Director of Parkway Medical Center in Birmingham, Ala. "Bunavail utilizes advanced drug delivery technology to fulfill an important need for treatment options with improved drug absorption and patient convenience, and as such, may help to address some of the challenges associated with sublingual administration and possibly help improve treatment compliance."
BDSI plans to launch the product in late third-quarter 2014 and estimates the peak sales potention of the drug to reach up to $250 million.